SLC67A1 and lung adenocarcinoma: In addition, we have also shown that SLC22A18 and SLC22A18AS expression levels are associated with clinical outcome; i.e., the overexpression of these genes was significantly correlated with worsening the progression of lung adenocarcinoma and SCC in patients.